UNITED STATES PATENT AND TRADEMARK OFFICE BEFORE THE PATENT TRIAL AND APPEAL BOARD PAR PHARMACEUTICAL, INC. Petitioner

v.

HYPERION THERAPEUTICS, INC. Patent Owner

Case IPR2015-01117*
Patent 8,642,012

PATENT OWNER HORIZON THERAPEUTICS, INC.'S CORRECTED PATENT OWNER RESPONSE PURSUANT TO 37 C.F.R. § 42.120



^{*} Case IPR2015-00283, instituted on a petition filed by Lupin Ltd. and Lupin Pharmaceuticals, Inc., has been joined with this proceeding.

TABLE OF CONTENTS

I.	INT	INTRODUCTION		
	A.	Background	1	
	B.	Relief Requested	2	
	C.	Related Proceedings	2	
	D.	Summary of Argument	2	
II.	REL	EVANT LAW	7	
III.	RELEVANT TECHNICAL BACKGROUND			
	A.	Nitrogen Retention Disorders	9	
	В.	Prior to August 2008, There was a Need for Reliable Biomarkers to Determine Effective Dosages of PAA Prodrugs	14	
	C.	Prior to August 2008, Conversion of PAA to PAGN was assumed to be Complete or Nearly Complete in UCD Patients	17	
	D.	The Development of the Inventions of the '012 Patent	23	
	E.	The Challenged Claims of the '012 Patent	24	
IV.	LEV	'EL OF SKILL IN THE ART	26	
V.	INT	ERPRETATIONS OF THE '012 PATENT CLAIMS	27	
VI.	THE	E SCOPE AND CONTENT OF THE PRIOR ART	28	
	A.	Brusilow '91	28	
	B.	Sherwin '19	30	
	C.	Shiple	32	
	D.	Comte	33	



	E.	Kasumov34	
	F.	Fernandes	
	G.	'647 Patent34	
VII.	ARGUMENT		
	A.	Petitioner's Argument that Claims 1, 3-4, 7-8, 10 and 12 are Obvious over Brusilow '91 in view of Sherwin '19, Comte and Shiple Fails Because it Hinges on Dr. Sondheimer's Misreading of Brusilow '91 in Combination with Sherwin '19, a Discredited Reference	
		 Petitioner's Assertion that a POSA Would Have Been Motivated to Combine Brusilow '91 with Sherwin 1919 Fails because Sherwin '19 was Later Discredited	
		2. Sherwin '19, Shiple and Comte Fail to Cure the Deficiencies of Brusilow '91 because a POSA would not have Understood those References to Teach or Suggest Incomplete Conversion47	
	В.	Petitioner's Argument that Claim 5 is Obvious over Brusilow '91 in view of Sherwin '19, Shiple and Fernandes Fails Because it Hinges on Dr. Sondheimer's Misreading of Brusilow '91 in Combination with Sherwin '19, a Discredited Reference	
	C.	Petitioner's Argument that Claims 2 and 9 are Obvious over Brusilow '91 in view of Sherwin '19, Shiple and the '647 patent Fails Because it Hinges on Dr. Sondheimer's Misreading of Brusilow '91 in Combination with Sherwin '19, a Discredited Reference	
	D.	Petitioner's Argument that Claims 6 and 11 are Obvious over Brusilow '91 in view of Sherwin '19, Shiple and Kasumov Fails Because it Hinges on Dr. Sondheimer's Misreading of Brusilow '91 in Combination with Sherwin '19, a Discredited Reference	
VIII.	CON	CLUSION54	



TABLE OF AUTHORITIES

Cases

Graham v. John Deere Co., 383 U.S. 1 (1966)	8
In re Cyclobenzaprine Hydrochloride Extended Release Capsule Patent Litig., 676 F.3d 1063 (Fed. Cir. 2012)	8
KSR Int'l Co. v. Teleflex Inc., 550 U.S. 398 (2007)	8
Panduit Corp. v. Dennison Mfg. Co., 810 F.2d 1561 (Fed. Cir. 1987)	9
Ricoh Co., Ltd. v. Quanta Computer, Inc., 550 F.3d 1325 (Fed. Cir. 2008)	9
Transocean Offshore Drilling v. Maersk Drilling USA, Inc., 699 F.3d 1340 (Fed. Cir. 2012)	8
Unigene Labs Inc. v. Apotex, Inc., 655 F.3d 1352 (Fed. Cir. 2011)	8
W.L. Gore & Assocs., Inc. v. Garlock, Inc., 721 F.2d 1540 (Fed. Cir. 1983)	9
Wyers v. Master Lock Co., 616 F.3d 1231 (Fed. Cir. 2010)	8
Statutes	
35 U.S.C. § 103(a)	7
Other Authorities	
MPEP 2141 02	9



I. INTRODUCTION

A. Background

The Board has ordered an investigation into the patentability of claims 1-12 (collectively "the challenged claims") of U.S. Patent No. 8,642,012 ("the '012 patent"). The present *inter partes* review has been instituted for the challenged claims solely on obviousness grounds.

Petitioner's obviousness arguments require combining features of several prior art publications. The prior art references at issue are Brusilow '91 (Ex. 1012), Comte (Ex. 1025), Shiple (Ex. 1017), Sherwin '19 (Ex. 1016), the '674 patent (Ex. 1018), Kausmov (Ex.1015) and Fernandes (Ex. 1011). Petitioner asserts various combinations of the cited references as rendering the challenged claims obvious, as seen in the summary table below:



Lupin Ltd. and Lupin Pharmaceuticals, Inc. ("Lupin") have filed a Petition for *inter partes* review of the '215 patent that is substantively identical to Par's Petition. (*See* Petition, Paper No. 1, IPR2016-00283.) Lupin filed an unopposed motion for joinder to the instant *inter partes* review but their motion has not yet been granted. (*See* Motion for Joinder, Paper No. 4 at 4, IPR2016-00284.)

DOCKET

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

